首页> 外文OA文献 >Amiloride selectively inhibits the urokinase-type plasminogen activator
【2h】

Amiloride selectively inhibits the urokinase-type plasminogen activator

机译:阿米洛利选择性抑制尿激酶型纤溶酶原激活剂

摘要

The diuretic drug amiloride, an inhibitor of Na+ uptake, competitively inhibits the catalytic activity of the urokinase-type plasminogen activator (u-PA), with a Ki of 7 X 10(-6) M. Generation of plasmin, cleavage of peptide substrates, and interaction of u-PA with a specific macromolecular proteinase inhibitor are all prevented in the presence of the drug. In contrast, amiloride does not affect the activity of either tissue-type plasminogen activator, plasmin, plasma kallikrein or thrombin. The inhibition of u-PA by amiloride may be related to the previously reported inhibition of u-PA-type enzymes by Na+. Amiloride or related compounds could prove useful in selectively controlling u-PA-catalyzed extracellular proteolysis.
机译:利尿剂阿米洛利(Na +吸收抑制剂)竞争性抑制尿激酶型纤溶酶原激活剂(u-PA)的催化活性,Ki为7 X 10(-6)M。纤溶酶的产生,肽底物的裂解,并且在药物存在下都阻止了u-PA与特定的大分子蛋白酶抑制剂的相互作用。相反,阿米洛利不影响组织型纤溶酶原激活物,纤溶酶,血浆激肽释放酶或凝血酶的活性。阿米洛利对u-PA的抑制作用可能与先前报道的Na +对u-PA型酶的抑制作用有关。阿米洛利或相关化合物可证明对选择性控制u-PA催化的细胞外蛋白水解有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号